Xabregas A, Gray L, Ham J M
Med J Aust. 1978 Jun 3;1(11):620-2. doi: 10.5694/j.1326-5377.1978.tb142009.x.
A double-blind controlled clinical trial of the efficacy of the prophylactic subcutaneous administration of calcium heparin in preventing deep vein thrombosis has been conducted in 50 patients with a fractured neck of the femur. Heparin was given every eight hours in a dose of 100 international units per kilogram of body weight and was commenced as soon as possible after the patient's admission to hospital. Treatment was continued for two weeks. In the placebo group, 12 of 25 patients developed a deep venous thrombosis and in five of these patients the thrombosis propagated to the thigh. There were no deep venous thromboses in the heparin-treated group during the two weeks of treatment, but four patients developed a deep venous thrombosis within a week of stopping the heparin. The heparin regime was safe; operative blood loss was not increased, nor was there an increased incidence of wound complications as compared to the placebo group.
对50例股骨颈骨折患者进行了一项双盲对照临床试验，以研究预防性皮下注射钙肝素预防深静脉血栓形成的疗效。肝素每8小时给药一次，剂量为每公斤体重100国际单位，患者入院后尽快开始给药。治疗持续两周。在安慰剂组中，25例患者中有12例发生深静脉血栓形成，其中5例患者的血栓扩展至大腿。在肝素治疗组治疗的两周内未发生深静脉血栓形成，但在停用肝素后的一周内有4例患者发生深静脉血栓形成。肝素治疗方案是安全的；与安慰剂组相比，手术失血量未增加，伤口并发症的发生率也未增加。
